Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Telling the truth about chemo may improve End-of-Life care

NCT ID NCT02606149

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether explaining the risks of chemotherapy more honestly to patients with incurable lung cancer could reduce the number who receive chemo in their last month of life. Researchers randomly assigned 123 patients to either standard information or a more detailed talk about how chemo might worsen life-threatening conditions. The goal was to see if better communication leads to less aggressive care and more focus on comfort and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could show that honest communication about chemotherapy risks helps patients avoid unnecessary treatment and improves end-of-life care quality.
What could go wrong
This is a small, single-center study testing a communication strategy, not a drug. Results may not apply broadly, and the intervention may not change patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

123 people

The number who actually took part.

Started

Jul 2016

Finished

Oct 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * stage IV lung cancer, histologically proven * \> 18 years old * diagnosed during the last 8 weeks * systemic therapy indicated Exclusion Criteria: * prior systemic therapy for metastatic disease * comorbidity not compatible with the inclusion according to the investigator * patient has not given its non-objection or not being able to give * patient unaffiliated or not beneficiary of a social security scheme

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Stage IV lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung cancer lung carcinoma lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Stage IV lung cancer

Contacts and locations

Locations

  • Hôpital Cochin

    Paris, Paris, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.